GlassScriptPhysician profile
David J Dwyer
NPI 1487715074
$2,745.87
in general payments reported to CMS, 2019-2025
29 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $344 · 2022: $214 · 2023: $547 · 2024: $737 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $351.11 | 2022-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $254.41 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $238.91 | 2022-2025 | Vraylar |
| Allergan, INC. | $221.33 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $189.09 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.79 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $174.61 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $138.57 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $137.85 | 2022-2025 | Spravato, Invega Sustenna |
| Gilead Sciences, INC. | $111.51 | 2023-2025 | |
| Lundbeck LLC | $79.78 | 2023-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $70.45 | 2019 | |
| Corium, LLC | $64.16 | 2023-2025 | Azstarys |
| Indivior INC. | $61.77 | 2019-2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $60.66 | 2025 | Cobenfy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $47.28 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $45.39 | 2019 | |
| Azurity Pharmaceuticals, INC. | $40.99 | 2023-2025 | Horizant, Horizant |
| Alkermes, INC. | $40.61 | 2022-2023 | Aristada, Lybalvi |
| Almatica Pharma LLC | $34.68 | 2023-2024 | Loreev Xr |
| Amarin Pharma, INC. | $32.34 | 2019-2020 | |
| Adlon Therapeutics L.P. | $31.12 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.09 | 2020 | |
| Astellas Pharma US INC | $22.81 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $21.74 | 2023 | Auvelity |
| Shire North American Group INC | $20.36 | 2019 | |
| Exact Sciences Corporation | $16.28 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $16.28 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dwyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.